Ultrasound contrast agent developer Sonus Pharmaceutical lastweek announced its plan to become a public company. The Bothell, WA, firm filed with the Securities and ExchangeCommission for an initial public offering of up to 2.5 millioncommon shares.
Ultrasound contrast agent developer Sonus Pharmaceutical lastweek announced its plan to become a public company.
The Bothell, WA, firm filed with the Securities and ExchangeCommission for an initial public offering of up to 2.5 millioncommon shares. Proceeds from the offering, to be made at $10 to$12 a share, will support ongoing R&D activities.
Sonus has completed phase II clinical testing of EchoGen, amicrobubble ultrasound contrast agent potentially useful in echocardiographyand perfusion procedures. It plans to file a new drug applicationwith the Food and Drug Administration by April 1, 1996.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
GE HealthCare Launches AI Mammography Platform with Key Applications from iCAD
November 30th 2023Offering an all-in-one platform of artificial intelligence (AI) applications, MyBreastAI Suite reportedly facilitates early breast cancer detection and enhances efficiency with breast imaging workflows.